Welcome to our dedicated page for Hookipa Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on Hookipa Pharma stock.
HOOKIPA Pharma Inc. reports asset-sale, governance, clinical and regulatory, and corporate-status developments tied to its history as a clinical-stage biopharmaceutical company developing immunotherapeutics for cancer and serious infectious diseases. Its disclosed programs included arenavirus-platform cancer vaccine assets such as HB-200 (eseba-vec) and HB-700, as well as HB-400 for hepatitis B virus and HB-500 for HIV.
Company updates have covered completed sales of oncology, HBV, and HIV program assets, collaboration-related activity, board and stockholder matters, operating and financial results, and the voluntary delisting and deregistration process for HOOKIPA common stock.
HOOKIPA Pharma reported a strong cash position of $142 million as of March 31, 2022, following a capital raise and collaboration with Gilead. The company is advancing its HB-200 program, with Phase 1 data expected mid-year and Phase 2 data expected in late 2022. However, revenue for Q1 2022 was $1.4 million, a decline from $5.3 million in Q1 2021, attributed to lower reimbursements under the Gilead collaboration. The net loss for the quarter was $18 million, slightly higher than the previous year's loss.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its first quarter 2022 financial results on May 16, 2022, before the market opens. The company specializes in developing novel immunotherapies using its proprietary arenavirus platform to enhance T cell responses against serious diseases. HOOKIPA's pipeline focuses on investigational immunotherapeutics targeting various cancers and aims to develop functional cures for HBV and HIV in partnership with Gilead. No conference call will accompany the earnings release.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced its participation in several investor conferences in May 2022. Key events include the BofA Securities 2022 Healthcare Conference from May 10-13, with a fireside chat on May 10 at 8:40am PT; the 2022 RBC Capital Markets Global Healthcare Conference on May 17-18, featuring a chat on May 17 at 4:05pm ET; and the H.C. Wainwright Global Investment Conference from May 23-26, with a chat on May 24 at 2:00pm ET. Webcasts will be available on their website, with archived replays accessible for 30 days.
HOOKIPA Pharma announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately. With over 30 years in the biotech industry, Baker has significantly contributed to HOOKIPA's strategic business collaborations and the development of its proprietary arenavirus platform. Her leadership is expected to bolster HOOKIPA's growth in novel immunotherapies targeting severe diseases. CEO Joern Aldag commended her experience and commitment to advancing the company's innovative pipeline.
HOOKIPA Pharma (NASDAQ: HOOK) has appointed Tim Reilly, Ph.D., to its Board of Directors, effective immediately. Reilly, a veteran in product development and early clinical trials, will enhance HOOKIPA's oncology initiatives, including the Phase 2 HB-200 program for head and neck cancer and preparations for the HB-300 prostate cancer program. His extensive experience includes 18 years at Bristol Myers Squibb, contributing to 12 therapy approvals. HOOKIPA focuses on innovative immunotherapies utilizing its proprietary arenavirus platform to target various cancers.
HOOKIPA Pharma announced positive preclinical data showcasing potent T cell responses and tumor control against cancer using its arenaviral platform. The results, presented at the AACR Annual Meeting, demonstrate effective combination strategies with 4-1BB agonists and adoptive T cell transfers. The company is preparing to file an IND for its HB-300 program targeting prostate cancer. Biomarker data from the ongoing HB-200 study in HPV16+ head and neck cancers indicate a significant induction of tumor antigen-specific T cell responses, further validating the potential of HOOKIPA's innovative immunotherapies.
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, announced participation in investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022. The company focuses on developing immunotherapies using its proprietary arenavirus platform, targeting various cancers, including HPV16+ and KRAS-mutated cancers. HOOKIPA aims to advance novel treatments that enhance T cell responses and is also working on functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma reported significant advancements in its oncology pipeline, notably with HB-200, which showed a 75% disease control rate in heavily pre-treated head and neck cancer patients. The candidate received FDA Fast Track designation and has advanced to a Phase 2 trial alongside pembrolizumab. Additionally, a collaboration with Gilead triggered a $54 million commitment. HOOKIPA ended 2021 with a pro forma cash position of $156.9 million. Despite a revenue decrease to $18.4 million in 2021 and a net loss of $75.7 million, the company projects funding into H1 2024, supporting ongoing and new programs.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer. Since joining in 2012, Orlinger has significantly contributed to the development of HOOKIPA’s arenavirus platform, enhancing its clinical potential in treating infectious diseases and cancers. CEO Joern Aldag highlighted his expertise and leadership role in advancing the company's immunotherapy initiatives. HOOKIPA continues to develop novel treatments targeting various cancers and aims for functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its fourth quarter and full year 2021 financial results on March 24, 2022, before market opening. A live conference call and webcast will take place at 8:30 AM ET to discuss these results and provide updates on corporate developments. HOOKIPA focuses on developing novel immunotherapies utilizing its proprietary arenavirus platform, targeting serious diseases including HPV16+ cancers and collaborating with Gilead on HBV and HIV functional cures.